← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-5 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
AntibodystaleMerck KGaA, Darmstadt, GermanyPhase 2

Atacicept (Atacicept)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#항체#면역항체+4
효능 ORR 87.5%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

adjuvant (Atezolizumab, Atezolizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 15.4%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

neoadjuvant (Atezolizumab, Atezolizumab (neoadjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 91.2%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + RP1)

Triple Negative Breast Neoplasms · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, 6-mercaptopurine, 6-thioguanine)

Solid Tumor, Adult; Metastatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Preclinical

Auto CAR-T (Auto CAR-T)

Plasma Cell Tumors · Plasma Cell Tumors

#PlasmaCellTumors#CGT#Preclinical#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleChristian Medical College, Vell…Phase 1

Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene (Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene)

Hemophilia A · CD3

#CD3#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleMedical College of WisconsinPhase 1

Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII (Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII)

Hemophilia A · CD3

#CD3#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleCity of Hope Medical CenterPhase 1

AutoCD6-CAR Treg cells (AutoCD6-CAR Treg cells)

Stage 3 Type 1 Diabetes · Stage 3 Type 1 Diabetes

#Stage3Type1Diabetes#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleAFA InsurancePhase 2

Autologous 3rd generation CD19-targeting CAR T cells (Autologous 3rd generation CD19-targeting CAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 7%임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes (Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes)

Relapsed or Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleOhio State University Comprehen…Phase 1

Autologous Anti-CD19/CD20/CD22 CAR T-cells (Autologous Anti-CD19/CD20/CD22 CAR T-cells)

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Recurrent Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 1%임상시험 1상태 DISCONTINUED
CGTBiologicstaleRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING

80 / 177 페이지

← 이전다음 →